Drug shortages are often common during an epidemic. However, the FDA has reported the first shortages linked to the COVID-19 Coronavirus according to ABC News.
The U.S. Food and Drug Administration announced it’s been alerted to the first manufacturing shortage of an unnamed drug, due to a viral coronavirus outbreak that began in China and has now reached American soil.
FDA Commissioner Stephen Hahn said the agency has been “closely monitoring” the medical product supply chain “with the expectation” that the outbreak of the novel coronavirus would “likely” have an impact.
“A manufacturer has alerted us to a shortage of a human drug that was recently added to the drug shortages list,” Hahn said in a statement Thursday night. “The manufacturer just notified us that this shortage is related to a site affected by coronavirus. The shortage is due to an issue with manufacturing of an active pharmaceutical ingredient used in the drug.” (source)
Shortages often increase the stock market values of the companies tied to them, as it creates a demand and their is a restriction on the supply.
As I have noted, biomedical holding will likely increase in value. This is not per se evidence in itself, but it certainly suggest that this trend will come to pass based on this example and many more that seem to be following around the world.